On October 25, 2023, Nykode Therapeutics AS closed the transaction. The company amended the terms of the transaction and announced that it has issued 29,549,400 new common shares at a price of NOK 17.10 per share for the gross proceeds of up to NOK 505.29474 million.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
13.98 NOK | -4.31% |
|
-5.62% | -34.86% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.86% | 446M | |
+16.44% | 122B | |
+18.94% | 113B | |
+18.11% | 26.22B | |
-25.37% | 19.01B | |
-20.02% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+4.35% | 13.84B |
- Stock Market
- Equities
- VACC Stock
- News Nykode Therapeutics
- Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding